Equity Profile

INCY

Incyte Corporation

Health CareBiotechnology$22.8B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Incyte Corporation (INCY) is a biotechnology company focused on discovering and developing innovative medicines for patients with serious diseases, particularly cancer. With a market cap of $23 billion, Incyte plays a significant role in the healthcare sector, especially in oncology, where new treatments are in high demand.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

Expected to be around $1.81.

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

Incyte's Q1 2026 earnings report surprised analysts with an EPS of $1.81, exceeding expectations by nearly 59%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continued focus on advancing clinical trials for new drugs.
Commitment to cost management to improve profitability.
Plans to provide more detailed revenue guidance in future reports.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Incyte's Q2 2026 earnings report, especially after strong EPS surprises in recent quarters. However, the lack of revenue guidance raises concerns about the sustainability of growth.

Bull Case

If Incyte reports strong EPS again and provides positive updates on its drug pipeline, it could lead to increased investor confidence and a potential stock rally.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides vague guidance on revenue, it could lead to a sell-off as investors reassess the company's growth prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.81.

EPS is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Pipeline Updates

Not available.

Updates on drug development and clinical trials can significantly impact investor sentiment and future revenue potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026, and how does it compare to the previous quarter?

Given the strong EPS surprises in recent quarters, the market will closely watch this figure to gauge ongoing profitability.

Will there be any updates on the drug pipeline and revenue projections?

Investors need clarity on future revenue sources, especially in light of the lack of guidance in previous reports.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Incyte to exceed EPS expectations again, given its recent track record of strong surprises.

Supporting Evidence

Incyte has beaten EPS estimates in 75% of the last eight quarters.

The options market is pricing a larger move than historical averages suggest, indicating heightened expectations.

Recent performance trends show a pattern of positive surprises that could continue.

Key Risk

If EPS comes in below $1.14, it could lead to a significant reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on profitability and future growth potential, as indicated by EPS and pipeline updates.

Bull Confirmed If

An EPS of $1.81 or higher, coupled with positive updates on the drug pipeline, would confirm the bull case.

Bear Confirmed If

An EPS below $1.14 or negative commentary on revenue projections would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move of about 15.5%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats EPS expectations and raises guidance, history suggests a potential stock increase of around 1.13% on the following day.

In-Line / Cautious

If results are in line with expectations but lack clarity on future growth, the stock may see muted reactions, reflecting uncertainty.

Miss

Should the company miss EPS expectations, history indicates a potential decline of about 0.18% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on clinical trial progress for new drugs.
2Details on cost management strategies and their impact on profitability.
3Insights into market conditions affecting revenue growth.
4Management's outlook on future revenue guidance.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

Expected to be around $1.81.

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

Management Promises & Guidance

Continued focus on advancing clinical trials for new drugs.
Commitment to cost management to improve profitability.
Plans to provide more detailed revenue guidance in future reports.

Expectations

Wall Street Expectations

Bull Case

If Incyte reports strong EPS again and provides positive updates on its drug pipeline, it could lead to increased investor confidence and a potential stock rally.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides vague guidance on revenue, it could lead to a sell-off as investors reassess the company's growth prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.81.

EPS is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Pipeline Updates

Not available.

Updates on drug development and clinical trials can significantly impact investor sentiment and future revenue potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026, and how does it compare to the previous quarter?

Given the strong EPS surprises in recent quarters, the market will closely watch this figure to gauge ongoing profitability.

Will there be any updates on the drug pipeline and revenue projections?

Investors need clarity on future revenue sources, especially in light of the lack of guidance in previous reports.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Incyte to exceed EPS expectations again, given its recent track record of strong surprises.

Supporting Evidence

Incyte has beaten EPS estimates in 75% of the last eight quarters.

The options market is pricing a larger move than historical averages suggest, indicating heightened expectations.

Recent performance trends show a pattern of positive surprises that could continue.

Key Risk

If EPS comes in below $1.14, it could lead to a significant reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on profitability and future growth potential, as indicated by EPS and pipeline updates.

Bull Confirmed If

An EPS of $1.81 or higher, coupled with positive updates on the drug pipeline, would confirm the bull case.

Bear Confirmed If

An EPS below $1.14 or negative commentary on revenue projections would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move of about 15.5%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats EPS expectations and raises guidance, history suggests a potential stock increase of around 1.13% on the following day.

In-Line / Cautious

If results are in line with expectations but lack clarity on future growth, the stock may see muted reactions, reflecting uncertainty.

Miss

Should the company miss EPS expectations, history indicates a potential decline of about 0.18% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on clinical trial progress for new drugs.
2Details on cost management strategies and their impact on profitability.
3Insights into market conditions affecting revenue growth.
4Management's outlook on future revenue guidance.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.